新的CRISPR方法检测血液中的罕见癌症突变,具有高度敏感性,有助于早期诊断和治疗监测。 A new CRISPR method detects rare cancer mutations in blood with high sensitivity, aiding early diagnosis and treatment monitoring.

韩国大学研究人员开发的以CRISPR为基础的称为MUTE-Seq的新技术,能够对血液样本中的稀有癌症突变进行高度敏感的检测,查明低至0.005%的变异性异频变化。 A new CRISPR-based technique called MUTE-Seq, developed by researchers at Korea University, enables highly sensitive detection of rare cancer mutations in blood samples, identifying changes present at as low as 0.005% variant allele frequency. 该方法利用经设计的酶去除正常的DNA并丰富肿瘤衍生的DNA,将突变信号提升到60倍,提高了检测最低残留疾病和早期癌症的准确性。 By using an engineered enzyme to remove normal DNA and enrich tumor-derived DNA, the method boosts mutation signals up to 60-fold, improving accuracy in detecting minimal residual disease and early-stage cancers. 它只使用50纳克的DNA,符合标准实验室程序,提高用于多癌症筛查、治疗跟踪和抗药性监测的液体生物感应器的可靠性。 It works with just 50 ng of DNA, is compatible with standard lab processes, and enhances the reliability of liquid biopsies for multi-cancer screening, treatment tracking, and resistance monitoring. 该方法于2025年11月在《高级材料》上发表,并刊登在期刊的封面上。 The approach was published in Advanced Materials in November 2025 and featured on the journal’s front cover.